68Ga-PSMA PET/CT and mpMRI for primary lymph node staging of intermediate to high-risk prostate cancer: a systematic review and meta-analysis of diagnostic test …
KCJ Yip, YL Li, S Chen, CL Ho… - Clinical and Translational …, 2021 - Springer
Purpose To evaluate the diagnostic accuracy of Gallium-68 prostate-specific membrane
antigen positron emission tomography-computed tomography (68 Ga-PSMA PET/CT) …
antigen positron emission tomography-computed tomography (68 Ga-PSMA PET/CT) …
Prostate cancer theranostics: from target description to imaging
IL Alberts, R Seifert, K Rahbar, A Afshar-Oromieh - PET clinics, 2021 - pet.theclinics.com
Prostate cancer (PC) is the most common malignancy in men, and the second leading cause
of cancer-related death in men. 1 Despite initial therapy at early-stage disease, biochemical …
of cancer-related death in men. 1 Despite initial therapy at early-stage disease, biochemical …
Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with …
K Huang, I Schatka, JMM Rogasch… - Annals of Nuclear …, 2021 - Springer
Objective Up to 60% of patients with metastatic, castration-resistant prostate cancer
(mCRPC) treated with 177 Lu prostate-specific membrane antigen (PSMA) radioligand …
(mCRPC) treated with 177 Lu prostate-specific membrane antigen (PSMA) radioligand …
Theranostics in oncology: What radiologists want to know
J Ferdinandus, WP Fendler, JJ Morigi, S Fanti - European Journal of …, 2021 - Elsevier
Combination of radioligand imaging and therapy, so called radiotheranostics, is a novel tool
of precision oncology with proven clinical value. In-depth knowledge of functional imaging …
of precision oncology with proven clinical value. In-depth knowledge of functional imaging …
[HTML][HTML] 177Lu-PSMA-617治疗转移性去势抵抗性前列腺癌新进展
温健男， 程超， 陈锐， 李葇， 姜鸿媛， 左长京 - 第二军医大学学报, 2021 - html.rhhz.net
姑息性手术, 试验性局部治疗, 外放射治疗, 内分泌治疗, 化学治疗等常规治疗手段对转移性去势
抵抗性前列腺癌(mCRPC) 患者的预后和生活质量改善效果有限. 以前列腺特异性膜抗原(PSMA) …
抵抗性前列腺癌(mCRPC) 患者的预后和生活质量改善效果有限. 以前列腺特异性膜抗原(PSMA) …
[PDF][PDF] PSMA-directed radioligand therapy (PSMA-RLT) with Lutetium-177 (177Lu-PSMA) as a treatment to metastatic resistant prostate cancer: a systematic review
LPH Helmich, MAM de Arruda, MT Sapienza - Revista De Medicina, 2021 - academia.edu
Prostate cancer is the second most prevalent in the world and an important cause of
mortality in elderly men. Its most severe form is metastatic castration-resistant prostate …
mortality in elderly men. Its most severe form is metastatic castration-resistant prostate …
[引用][C] Salvage Radioligand Therapy with Repeated Cycles of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow …
D Groener, J Baumgarten, S Haefele, C Happel… - 2021 - s Note: MDPI stays neutral with …
PT-BR: Radioterapia PSMA-ligante dirigida com Lutécio 177 como um tratamento para câncer de próstata resistente a castração: uma revisão sistemática
LPH Helmich, MAM de Arruda, MT Sapienza - Revista de Medicina, 2021 - revistas.usp.br
O câncer de próstata é o segundo mais prevalente no mundo, sendo uma importante causa
de mortalidade dentre homens idosos. Sua forma mais séria é o câncer metastático …
de mortalidade dentre homens idosos. Sua forma mais séria é o câncer metastático …
Prostate Cancer Theranostics
A theranostic can broadly be defined as an agent used for disease detection and therapy.
Here we focus on imaging-based theranostics. While the concept has been in practice for …
Here we focus on imaging-based theranostics. While the concept has been in practice for …